NASA continues building next-gen Roman Space Telescope despite budget worries
NASA engineers have successfully completed testing on one half of the Nancy Grace Roman Space Telescope — a key step in making sure this future observatory will perform as expected once it reaches space.
"This milestone tees us up to attach the flight solar array sun shield to the outer barrel assembly, and deployable aperture cover, which we'll begin this month," said Jack Marshall, who leads integration and testing for these Roman Space Telescope elements at NASA's Goddard Space Flight Center in Greenbelt, Maryland.
"Then we'll complete remaining environmental tests for the flight assembly before moving on to connect Roman's two major assemblies and run the full observatory through testing, and then we'll be ready to launch!" he continued.
Launch is expected to occur sometime in early 2027. That timeline, however, could still be up in the air as the White House plans to slash NASA's budget in 2026. The drastic 24% cut — the largest in NASA's history — would affect major projects like the Gateway moon-orbiting space station and Mars sample return, among others. Previously released "passback documents," which also describe possible White House fiscal year budget scenarios, suggested funding will be given for the Hubble Space Telescope and James Webb Space Telescope but not other telescopes. However, the agency is still awaiting a finalized budget.
For now, engineers are continuing their work on Roman. Back in January, before thermal testing could begin, engineers attached the telescope's visor-like sunshade called the "deployable aperture cover" to the telescope's outer barrel assembly, which will eventually house its powerful instruments. By March, they'd also added a set of test solar panels.
In April, this entire setup was moved into the Space Environment Simulator at NASA's Goddard Space Flight Center in Maryland — a giant chamber that mimics the harsh hot-and-cold temperatures Roman will face in space. Of note, those aforementioned passback documents had reportedly suggested the White House's possible cuts to NASA funding could see Goddard Space Flight Center shut down entirely.
Related Stories:
— NASA installs 'bulletproof' sunshade on powerful Nancy Grace Roman Space Telescope (photos)
— Trump's 2026 budget plan would cancel NASA's Mars Sample Return mission. Experts say that's a 'major step back'
— Experts alarmed as White House proposes 'largest single-year cut to NASA in American history'
"The test verifies the instruments will remain at stable operating temperatures even while the sun bakes one side of the observatory and the other is exposed to freezing conditions — all in a vacuum, where heat doesn't flow as readily as it does through air," said Jeremy Perkins, an astrophysicist serving as Roman's observatory integration and test scientist at NASA Goddard.
Once Roman is out in orbit nearly a million miles from Earth, there's no easy way to send astronauts to fix it. That's why NASA engineers work tirelessly to make sure everything deploys and operates flawlessly. No second chances.
Technicians are gearing up to connect Roman's two main sections this November. Once joined, the telescope will officially become a fully assembled observatory by the end of the year. After final testing is complete, Roman will be packed up and shipped to NASA's Kennedy Space Center in Florida to begin launch preparations in summer 2026.
NASA scientists say the mission remains on schedule, though they are working hard toward the possibility of an even earlier liftoff as soon as fall 2026.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Ultra-processed foods that fuel colon cancer — and healthy alternatives that may offset the damage
Growing evidence has linked the rise in colon cancer cases to ultra-processed foods that fill our diets. Researchers found tumors are fueled by Inflammatory compounds and a lack of compounds linked to healing. Foods such as leafy greens and fish may help pinpoint disease-fighting molecules to stave off cancer. As colon cancer diagnoses are on the rise in younger people, researchers are discovering that certain foods may help or hurt our odds of developing the disease. A team of scientists from the University of South Florida and Tampa General Hospital Cancer Institute may have found clues in compounds called bioactive lipids, molecules that can increase or decrease inflammation in the body. In a study published late last year, the researchers analyzed more than 100 tumor samples from patients and found that they contained a higher proportion of these inflammation-causing compounds compared with healthy tissue. Previous evidence has linked increased inflammation to diets high in ultra-processed food, such as chips, sausages, packaged desserts, and refined carbs. As processed food takes up a growing share of the American diet (more than half, recent CDC data shows), a growing number of younger people are being diagnosed with colon cancer. It's now the second-leading cause of cancer-related death in the US. But inflammation isn't just a red flag that the body is under stress: tracking it can help doctors and scientists find ways to bolster the immune system against disease, slowing or stopping tumor growth by cutting back on inflammatory compounds and boosting healthy ones. For instance, the research team found that the tumors were lacking in molecules associated with healing and lowering inflammation. One source of these molecules is our diet, which includes foods such as leafy greens and seafood rich in omega-3 fatty acids. Eating more of these gut-friendly foods and fewer packaged meals may help keep inflammation at bay for better health. "If the molecules are coming from processed food products, they directly imbalance the immune system and drive chronic inflammation," Ganesh Halade, a professor at the University of South Florida Health Heart Institute who coauthored the study, said in a press release. "Our bodies are designed to actively resolve inflammation through bioactive lipid compounds derived from the healthy fats, like avocados, that we consume." While people who follow a "clean" diet can still get cancer, understanding the role of food could give us more tools to fight cancer. Fighting cancer with fish oil Cancer is like a "chronic wound that won't heal," Dr. Timothy Yeatman, a professor of surgery at the University of South Florida who's the senior author of the tumor study, said in the release. A daily diet of ultra-processed foods can make it harder for the body to fight off tumors because of the increased inflammation, he said in a press release. In particular, foods that cancer doctors avoid include processed meats and sugary treats, both of which are linked to higher odds of illnesses, including cancer and cardiovascular disease. While it's not news that spinach and seafood are better for you than bacon and doughnuts, zeroing in on the link between food and inflammation unlocks more effective strategies to stave off disease in the future. For example, the Tampa General Hospital Cancer Institute has conducted early trials of a modified form of fish oil with promising results for reducing inflammation. "This has the potential to revolutionize cancer treatment, moving beyond drugs to harness natural healing processes," Yeatman said. "It's a vital step toward addressing chronic inflammation and preventing diseases before they start." For now, one of the best ways to prevent cancer is to catch it early with routine testing. As far as eating your way to better health, evidence suggests your best bet is sticking to mostly whole, unprocessed foods such as veggies, fruits, legumes, lean proteins, and whole grains for a longer, healthier life."This has the potential to revolutionize cancer treatment, moving beyond drugs to harness natural healing processes," Yeatman said. "It's a vital step toward addressing chronic inflammation and preventing diseases before they start." In the meantime, there's evidence that your best bet for a longer, healthier life is sticking to a diet of mostly whole, unprocessed foods such as veggies, fruits, legumes, lean proteins, and whole grains. Read the original article on Business Insider Solve the daily Crossword
Gizmodo
an hour ago
- Gizmodo
Satellite Captures Awesome Power of Tsunami Triggered by Epic Russian Quake
In late July, the sixth biggest earthquake in recorded history struck off the coast of Russia's Kamchatka Peninsula. The magnitude 8.8 quake triggered a tsunami that sent waves across the Pacific, prompting widespread warnings and some evacuation orders. Data released Thursday, August 14, by NASA Earth Observatory captures this global event in striking detail. The Surface Water and Ocean Topography (SWOT) satellite, a joint venture between NASA and the French space agency CNES (Centre National d'Études Spatiales), recorded the tsunami's leading edge about 70 minutes after the earthquake struck. In the animated graphic below, the darkest red spots mark places where the wave rose more than 1.5 feet (0.45 meters). 'A 1.5-foot-tall wave might not seem like much, but tsunamis are waves that extend from the seafloor to the ocean's surface,' Ben Hamlington, an oceanographer at NASA's Jet Propulsion Laboratory in Southern California, said in a NASA Earth Observatory release. 'What might only be a foot or two in the open ocean can become a 30-foot wave in shallower water at the coast.' Earthquakes trigger tsunamis when they are large enough to displace huge volumes of ocean water. Picture the entire water column around the disturbance suddenly lifting. The tsunami triggered by this magnitude 8.8 quake was actually less powerful than expected, but it still sent waves up to 13 feet (4 meters) high barreling into coastal towns in Kamchatka near the quake's epicenter, according to the BBC. One person caught the massive swell on video while walking his dog along coastal cliffs. Other affected locations, including the U.S. West Coast, Hawaii, and Japan, experienced much smaller waves. Tsunami warnings were quickly downgraded or lifted in most areas. By gathering data on the height, shape, and direction of tsunami waves, SWOT is helping scientists at NOAA's Center for Tsunami Research improve their forecast model. 'The satellite observations help researchers to better reverse engineer the cause of a tsunami, and in this case, they also showed us that NOAA's tsunami forecast was right on the money,' Josh Willis, an oceanographer at NASA's Jet Propulsion Laboratory, said in the release. NOAA issues alerts to coastal communities potentially in the path of a tsunami based on outputs from its forecast model, so it's critical that it's as accurate as possible. When the Center for Tsunami Research tested its model with SWOT's tsunami data, the results were exciting, said chief scientist Vasily Titov, according to the release. 'It suggests SWOT data could significantly enhance operational tsunami forecasts.'
Yahoo
an hour ago
- Yahoo
Shuttle Pharma Provides Second Quarter 2025 Corporate Update
GAITHERSBURG, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ('Shuttle Pharma' or the 'Company'), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update. Recent Activities: Patient enrollment in the Company's Phase 2 clinical trial of Ropidoxuridine for treatment of patients with glioblastoma reached 63% in the initial randomized portion of the trial. 72% of the enrolled patients have completed all seven cycles. Ropidoxuridine is being reported by treatment sites as well tolerated. Ended the quarter with $4.8 million in cash following the closing of a private placement pursuant to a securities purchase agreement with an accredited investor for aggregate gross proceeds of $4.25 million in June 2025. Completed a reverse stock split in June 2025 as part of strategic Nasdaq compliance initiative. Appointed George Scorsis as the Chairman of the Board of Directors and appointed Christopher Cooper, our current Interim Chief Executive Officer to our Board of Directors. Mr. Scorsis has over 25 years of experience leading companies in highly regulated industries to rapid growth. Mr. Cooper has over 27 years of management and finance experience. 'We are encouraged by the progress in our Phase 2 clinical trial of Ropidoxuridine for glioblastoma, with 63% enrollment having recently been achieved. Importantly, 72% of enrolled patients have completed all seven cycles with treatment reported as being well-tolerated,' commented Shuttle Pharma's interim Chief Executive Officer, Chris Cooper. 'We are working closely with our primary third-party CRO, Theradex Systems, to continue execution of the clinical trial in combination with leading cancer centers across the U.S. Our goal continues to remain completion of enrollment later this year, with follow-up and data readouts anticipated in 2026.' Ropidoxuridine (IPdR) is Shuttle Pharma's lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure. Shuttle Pharma previously received Orphan Drug Designation from the FDA, providing Shuttle Pharma with potential marketing exclusivity upon obtaining FDA approval for treatment of this disease. The Phase 2 clinical trial design initially randomizes 40 patients into two different dose levels of drug, with 20 patients receiving 1,200 mg/day and 20 patients receiving 960 mg/day, to determine an optimal dose for use in glioblastoma patients in combination with RT. After the optimal dose is identified, 14 additional patients will be enrolled at the optimal dose to reach statistical significance with the end-point demonstrating increased survival as compared to historical controls. The Phase 2 clinical trial is conducted at Georgetown University Medical Center, Allegheny Health Network (AHN) Cancer Institute, UNC Medical Center, the UVA Cancer Center, John Theurer Cancer Center at Hackensack University Medical Center, and Miami Cancer Institute, part of Baptist Health South Florida. An estimated 800,000 patients in the US are treated with radiation therapy for their cancers yearly. According to the American Cancer Society and the American Society of Radiation Oncologists, about 50% are treated for curative purposes and the balance for palliative therapeutic care. The market opportunity for radiation sensitizers lies with the 400,000 patients treated for curative purposes, with this number expected to grow by more than 22% over the next five years. More information about the Phase 2 study (NCT06359379) can be found at About Shuttle Pharmaceuticals Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at Safe Harbor Statement Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' These statements include, but are not limited to, statements concerning the development of our company. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the 'Risk Factors' section of Shuttle Pharma's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025, as well other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Shuttle PharmaceuticalsChris Cooper Interim Chief Executive Officerinfo@ Investor ContactsLytham Partners, LLC602-889-9700shph@ in to access your portfolio
